X0306 4 2016-09-01 1 0001416792 Relypsa Inc RLYP 0001591469 Krasnow Ronald A. C/O RELYPSA, INC. 100 CARDINAL WAY REDWOOD CITY CA 94063 0 1 0 0 See Remarks Common Stock 2016-09-01 4 A 0 2917 0.00 A 17646 D Common Stock 2016-09-01 4 U 0 3479 32.00 D 14167 D Common Stock 2016-09-01 4 D 0 14167 32.00 D 0 D Stock Option (Right to Buy) 18.87 2016-09-01 4 A 0 11667 0.00 A 2016-09-01 2025-11-05 Common Stock 11667 17500 D Stock Option (Right to Buy) 18.87 2016-09-01 4 D 0 17500 D 2025-11-05 Common Stock 17500 0 D Stock Option (Right to Buy) 4.65 2016-09-01 4 D 0 17441 D 2020-09-28 Common Stock 17441 0 D Stock Option (Right to Buy) 3.96 2016-09-01 4 D 0 8783 D 2021-09-13 Common Stock 8783 0 D Stock Option (Right to Buy) 3.96 2016-09-01 4 D 0 37611 D 2022-09-27 Common Stock 37611 0 D Stock Option (Right to Buy) 7.40 2016-09-01 4 D 0 43603 D 2023-07-23 Common Stock 43603 0 D Stock Option (Right to Buy) 27.21 2016-09-01 4 D 0 24500 D 2024-08-13 Common Stock 24500 0 D Stock Option (Right to Buy) 28.38 2016-09-01 4 D 0 24500 D 2025-08-09 Common Stock 24500 0 D On November 6, 2015, the Reporting Person was granted 4,375 Restricted Stock Units to vest upon achievement of certain performance-based milestones (the "Performance RSUs"). On June 3, 2016, 1/3rd of the Performance RSUs vested upon achievement of the first performance milestone. On September 1, 2016, the vesting of the remaining Performance RSUs accelerated in full with any performance condition being deemed achieved at 100% pursuant to the terms of the Agreement and Plan of Merger, dated as of July 20, 2016 (the "Merger Agreement"), by and among the Issuer, Galencia AG, a public limited company existing under the laws of Switzerland ("Parent"), and Vifor Pharma USA Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent. Disposed of pursuant to the Merger Agreement in exchange for cash consideration of $32.00 per share, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, on September 1, 2016, each award of restricted stock units and stock options was cancelled in exchange for the right to receive $32.00 per share in cash less any applicable withholding taxes and in the case of stock options, less the applicable exercise price. On November 6, 2015, the Reporting Person was granted an option to purchase 17,500 shares of Common Stock to vest in three equal tranches upon achievement of certain performance-based milestones (the "Performance Option"). On June 3, 2016, 1/3rd of the Performance Option vested upon achievement of the first performance milestone. On September 1, 2016, the vesting of the remaining unvested shares subject to the Performance Option accelerated in full with any performance condition being deemed achieved at 100% pursuant to the terms of the Merger Agreement. General Counsel, SVP and Secretary /s/ Ronald A. Krasnow 2016-09-02